Eledon Pharmaceuticals Inc (ELDN)

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer...

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN...

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet...

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]